eli lilly glp-1 - Search News

News

Eli Lilly weight loss pill shows promise

NBC News · 19h

Eli Lilly says new GLP-1 weight loss pill could reach market in 2026

Drugmaker Eli Lilly says after successful results in a phase 3 clinical trial, it expects to submit a GLP-1 weight loss pill for FDA approval by the end of the year. The pill does not produce the same amount of weight loss as injections,

USA TODAY · 32m

Eli Lilly closer to breakthrough weight loss drug; shares tumble as some question results

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial saw people lose 12% of body weight.

CNN on MSN · 1d

Experimental GLP-1 pill helped people with obesity lose weight, Eli Lilly says

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that it helped people lower their weight by an average of 12% after 72 weeks.

22h

Eli Lilly second quarter earnings beat on strong GLP-1 sales, but stock dives on GLP-1 pill trial results

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

4hon MSN

Eli Lilly Stock Is On Track for Its Worst Performance Since 2008. Should Investors Be Worried?

The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst ...

1d

Daily oral GLP-1 pill could be just as effective as weekly shots: Drugmaker

Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 shots.

1d

Where Eli Lilly stands after Q2 beat but weak GLP-1 pill data

Eli Lilly (LLY) raised its full-year forecast after beating second quarter expectations, but shares slipped as its ...

2don MSN

Can Eli Lilly keep its GLP-1 crown? Q2 earnings will tell

Eli Lilly (LLY) reports Q2 earnings on Aug 7, with booming diabetes and weight-loss drug sales driving strong growth.

Fierce Pharma2d

Novo's outgoing CEO prepares to hand off business as sales threats from Lilly, GLP-1 compounders persist

On the one hand, the company is struggling to stay competitive with its chief rival Eli Lilly, and on the other, compounders ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results